Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 13, Issue 12, Pages 12153-12168
Publisher
MDPI AG
Online
2012-09-26
DOI
10.3390/ijms131012153
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
- (2012) Anke Reinacher-Schick et al. BMC CANCER
- Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
- (2012) Mi-Jung Kim et al. BMC CANCER
- Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
- (2012) M Pichler et al. BRITISH JOURNAL OF CANCER
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- The prognostic value of KRAS mutations in patients with colorectal cancer
- (2012) YASUHIRO INOUE et al. ONCOLOGY REPORTS
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- LIN28B Promotes Colon Cancer Progression and Metastasis
- (2011) C. E. King et al. CANCER RESEARCH
- Inhibition of Ras for cancer treatment: the search continues
- (2011) Antonio T Baines et al. Future Medicinal Chemistry
- Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
- (2011) Cecily P. Vaughn et al. GENES CHROMOSOMES & CANCER
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms
- (2011) C E King et al. ONCOGENE
- Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
- (2010) C Bengala et al. BRITISH JOURNAL OF CANCER
- Role of anti-oncomirs miR-143 and -145 in human colorectal tumors
- (2010) Y Akao et al. CANCER GENE THERAPY
- miRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer
- (2010) S. Yu et al. CANCER RESEARCH
- MicroRNA in colorectal cancer: from benchtop to bedside
- (2010) W. K. K. Wu et al. CARCINOGENESIS
- LIN28B confers radio-resistance through the posttranscriptional control of KRAS
- (2010) Sun-Hye Jeong et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Recently identified and potential targets for colon cancer treatment
- (2010) Michael A Lea Future Oncology
- Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
- (2010) Inti Zlobec et al. INTERNATIONAL JOURNAL OF CANCER
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of MicroRNA Expression with Microsatellite Instability Status in Colorectal Adenocarcinoma
- (2010) Jonathan S.L. Earle et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
- (2010) Monique Maas et al. LANCET ONCOLOGY
- KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases
- (2009) Garrett M. Nash et al. ANNALS OF SURGICAL ONCOLOGY
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells
- (2009) Pedro M. Borralho et al. FEBS Journal
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
- (2009) Salvatore Siena et al. JNCI-Journal of the National Cancer Institute
- Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
- (2009) Nicola Normanno et al. Nature Reviews Clinical Oncology
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of miR-143 targeting KRAS in colorectal tumorigenesis
- (2009) X Chen et al. ONCOGENE
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
- (2008) D. Santini et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More